Clinical Trial Update: A Study of GWP42003 as Adjunctive Therapy in the First Line Treatment of Schizophrenia or Related Psychotic Disorder [Phase 2]

View source ↗

Summary

Phase 2 trial of GWP42003 as adjunctive therapy for first-line schizophrenia or related psychotic disorder completed; results posted in 2019.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Schizophrenia
• Schizophrenia-related Psychotic Disorder

Drugs mentioned

• GWP42003

Snippet

Sponsor: Jazz Pharmaceuticals | Conditions: Schizophrenia, Schizophrenia-related Psychotic Disorder | Phase 2 | Status: COMPLETED | Results posted: 2019-07-26